25 studies found for:    prostate cancer, psma, treat
Show Display Options
Rank Status Study
1 Enrolling by invitation An Open-label Treatment Extension of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Condition: Prostate Cancer
Intervention: Drug: PSMA ADC
2 Recruiting Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)
Condition: Prostate Cancer
Interventions: Biological: engineered autologous T cells;   Drug: cyclophosphamide
3 Active, not recruiting
Has Results
PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment
Condition: Prostate Cancer
Interventions: Biological: Peptide Vaccine;   Drug: Poly IC-LC
4 Completed Vaccine Therapy of Prostate Cancer Patients With Recombinant Soluble Prostate-Specific Membrane Antigen (Rs-PSMA) Plus the Immunological Adjuvant Alhydrogel
Condition: Prostate Cancer
Intervention: Biological: rsPSMA protein plus Alhydrogel® vaccine
5 Completed Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Condition: Prostate Cancer
Interventions: Biological: PSA prostate cancer vaccine;   Biological: recombinant interleukin-12
6 Withdrawn Study of a Drug [DCVax (tm)-Prostate] to Treat Prostate Cancer When Hormone Therapy is no Longer Effective.
Condition: Prostate Cancer
Intervention: Drug: Dendritic cell immunotherapy
7 Completed Extended Study of Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: PSMA ADC
8 Recruiting Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer
Condition: Prostate Cancer
Interventions: Biological: androgen ablation + dendritic cell vaccine;   Biological: androgen ablation plus dendritic cell vaccine
9 Not yet recruiting Imaging of Residual Tumor During Prostatectomy
Conditions: Prostate Cancer;   Prostatectomy
Intervention:
10 Unknown  Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Condition: Prostate Cancer
Interventions: Biological: PSA prostate cancer vaccine;   Biological: therapeutic autologous dendritic cells
11 Withdrawn Phase 2 Study of G-202 in Patients With Chemotherapy-Naïve Metastatic Castrate-Resistant Prostate Cancer
Condition: Prostate Cancer.
Intervention: Drug: G-202
12 Unknown  GVAX in Advanced Prostate Cancer Patients Made Lymphopenic
Condition: Prostate Cancer
Intervention: Biological: GM-CSF gene transduced allogeneic vaccine GVAX
13 Terminated Phase 1 Trial of Ipilimumab and GVAX in Patients With Metastatic Castration-resistant Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: GVAX and ipilimumab
14 Completed Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: PSMA ADC
15 Recruiting A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Condition: Prostate Cancer
Intervention: Drug: PSMA ADC
16 Recruiting Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning
Condition: Prostate Cancer
Intervention: Biological: Gene Modified T Cells
17 Recruiting Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning
Condition: Monitor Adverse Events
Intervention: Drug: Anti-PSMA Designer T Cells
18 Unknown  Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Docetaxel;   Drug: Prednisone;   Drug: 177Lu-J591
19 Active, not recruiting Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging in Men With Prostate Cancer Undergoing Prostatectomy and/or Pelvic Lymph Node Dissection
Condition: Prostate Cancer
Intervention: Drug: 99mTc-MIP-1404
20 Active, not recruiting Clinical and Molecular Correlates of Positron Emission Tomography (PET) With 89Zr-DFO-huJ591 in Metastatic Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: 89Zr-DFO-huJ591

Previous Page Studies Shown (1-20) Next Page (21-25) Show next page of results
Indicates status has not been verified in more than two years